Literature DB >> 19428077

Prostate-specific antigen bounce after prostate brachytherapy: review of a confusing phenomenon.

Murat Caloglu1, Jay Ciezki.   

Abstract

Prostate brachytherapy is a commonly used modality for the treatment of prostate cancer. After prostate brachytherapy, the prostate-specific antigen (PSA) level may fluctuate and increase temporarily without a clear reason in 30-40% of successfully treated men. This phenomenon is called "PSA bounce" and engenders anxiety on the part of the patient and physician. Having reviewed the literature we found 19 articles and summarized in the current review to delineate the facts of this relatively common and ambiguous phenomenon. Although several patient and treatment related factors were assessed by studies, only age remained as the most consistent predictor.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19428077     DOI: 10.1016/j.urology.2009.01.043

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  19 in total

1.  125I brachytherapy in younger prostate cancer patients : Outcomes in low- and intermediate-risk disease.

Authors:  Isabelle Kindts; Karin Stellamans; Ignace Billiet; Hans Pottel; Antoon Lambrecht
Journal:  Strahlenther Onkol       Date:  2017-05-09       Impact factor: 3.621

2.  [Prostate-specific antigen for treatment monitoring].

Authors:  M Graefen; M Fröhner; M Wirth
Journal:  Urologe A       Date:  2011-03       Impact factor: 0.639

3.  Nucleotide resolution analysis of TMPRSS2 and ERG rearrangements in prostate cancer.

Authors:  Christopher Weier; Michael C Haffner; Timothy Mosbruger; David M Esopi; Jessica Hicks; Qizhi Zheng; Helen Fedor; William B Isaacs; Angelo M De Marzo; William G Nelson; Srinivasan Yegnasubramanian
Journal:  J Pathol       Date:  2013-06       Impact factor: 7.996

4.  Multiparametric prostate MR imaging with T2-weighted, diffusion-weighted, and dynamic contrast-enhanced sequences: are all pulse sequences necessary to detect locally recurrent prostate cancer after radiation therapy?

Authors:  Olivio F Donati; Sung Il Jung; Hebert Alberto Vargas; David H Gultekin; Junting Zheng; Chaya S Moskowitz; Hedvig Hricak; Michael J Zelefsky; Oguz Akin
Journal:  Radiology       Date:  2013-03-12       Impact factor: 11.105

5.  Prostate-specific antigen kinetics after I125-brachytherapy for prostate adenocarcinoma.

Authors:  Alessia Guarneri; Angela Botticella; Riccardo Ragona; Andrea Riccardo Filippi; Fernando Munoz; Giovanni Casetta; Paolo Gontero; Alessandro Tizzani; Umberto Ricardi
Journal:  World J Urol       Date:  2012-08-26       Impact factor: 4.226

6.  Rapid Increase of the Serum PSA Level in Response to High-Intensity Focused Ultrasound Therapy may be a Potential Indicator of Biochemical Recurrence of Low- and Intermediate-Risk Prostate Cancer.

Authors:  Teruo Inamoto; Kazumasa Komura; Toshikazu Watsuji; Haruhito Azuma
Journal:  Clin Med Insights Oncol       Date:  2011-04-19

7.  Distinguishing prostate-specific antigen bounces from biochemical failure after low-dose-rate prostate brachytherapy.

Authors:  Cian Hackett; Sunita Ghosh; Ron Sloboda; Kevin Martell; Lanna Lan; Nadeem Pervez; John Pedersen; Don Yee; Albert Murtha; John Amanie; Nawaid Usmani
Journal:  J Contemp Brachytherapy       Date:  2014-09-05

8.  Tumour and immune cell dynamics explain the PSA bounce after prostate cancer brachytherapy.

Authors:  Yoichiro Yamamoto; Chetan P Offord; Go Kimura; Shigehiko Kuribayashi; Hayato Takeda; Shinichi Tsuchiya; Hisashi Shimojo; Hiroyuki Kanno; Ivana Bozic; Martin A Nowak; Željko Bajzer; David Dingli
Journal:  Br J Cancer       Date:  2016-07-12       Impact factor: 7.640

9.  Prostate-specific antigen bounce following stereotactic body radiation therapy for prostate cancer.

Authors:  Charles C Vu; Jonathan A Haas; Aaron E Katz; Matthew R Witten
Journal:  Front Oncol       Date:  2014-01-28       Impact factor: 6.244

Review 10.  Multiparametric MRI for recurrent prostate cancer post radical prostatectomy and postradiation therapy.

Authors:  Flavio Barchetti; Valeria Panebianco
Journal:  Biomed Res Int       Date:  2014-05-25       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.